|
Mutation Information
|
Mutation Site
|
G163R |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.G163R+in.Q148R+in.G140A+in.E138A |
|
Genotype/Subtype
|
A |
|
Viral Reference
|
NL4.3
|
|
Relevant Drug
|
raltegravir (RAL);elvitegravir (EVG);dolutegravir (DTG) |
|
Country
|
Uganda |
Literature Information
|
PubMed PMID
|
32853364
|
|
Clinical information
|
Yes
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. |
|
Author
|
Ndashimye E,Avino M,Olabode AS,Poon AFY,Gibson RM,Li Y,Meadows A,Tan C,Reyes PS,Kityo CM,Kyeyune F,Nankya I,Quiñones-Mateu ME,Arts EJ |
|
Evidence
|
Two patients, one with E138A/G140A/Q148R/G163R and one with E138K/G140A/S147G/Q148K, displayed the highest reported resistance to raltegravir, elvitegravir and even dolutegravir.
|
|
|
HIV Mutation Detail Information